Dexter Devanand Hadley, MD | |
3400 Spruce St, One Maloney, Philadelphia, PA 19104-4206 | |
(215) 662-6156 | |
Not Available |
Full Name | Dexter Devanand Hadley |
---|---|
Gender | Male |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 3400 Spruce St, Philadelphia, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013143460 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | MT195738 (Pennsylvania) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | MT195738 (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dexter Devanand Hadley, MD 3400 Spruce St, One Maloney, Philadelphia, PA 19104-4206 Ph: (215) 662-6156 | Dexter Devanand Hadley, MD 3400 Spruce St, One Maloney, Philadelphia, PA 19104-4206 Ph: (215) 662-6156 |
News Archive
How the brain lets us perceive and navigate the world is one of the most fascinating aspects of cognition. When orienting ourselves, we constantly combine information from all six senses in a seemingly effortless way - a feature that even the most advanced AI systems struggle to replicate.
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).
The annual premium for a family health plan sponsored by an employer cost about 54 percent more in 2009 than it did in 2000, $13,027 and $8,437 (adjusted for inflation), respectively, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Medica Corporation, a provider of easy-to-use, low-cost blood testing analyzers, announced today the global release of its EasyCell assistant cell image analyzer for hematology laboratories.
Results from HPTN 067, a Phase II, randomized, open-label study, demonstrate most study participants had higher coverage of sex events and better adherence when they were assigned to the daily dosing arm, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.
› Verified 7 days ago